PAI-1, t-PA and circulating hTERT DNA as related to virus infection in liver carcinogenesis

Anticancer Research

Volumn 28, Issue 1 A, 2008, Pages 223-228

  Divella, Rosa ^a   Lacalamita, Rosanna ^a   Tommasi, Stefania ^a   Coviello, Maria ^a   Daniele, Antonella ^a   Garrisi, Vito Michele ^a   Abbate, Ines ^a   Simone, Giovanni ^a   Gadaleta, Cosimo ^a   Paradiso, Angelo ^a   Quaranta, Michele ^a  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

Author keywords

Circulating hTERT DNA; Hepatocellular carcinoma; PAI 1; t PA

Indexed keywords

ALPHA FETOPROTEIN; DNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; TELOMERASE REVERSE TRANSCRIPTASE; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CARCINOGENESIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; MALE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AGED; AGED, 80 AND OVER; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; CELL TRANSFORMATION, NEOPLASTIC; DNA, NEOPLASM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; TELOMERASE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 40549120297     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. El-Serag HB and Mason AC: Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340: 745-750, 1999.
2. Shirabe K, Takenaka K and Taketomi A: Postoperative hepatitis status as a significant risk factor for recurrence in cirrhotic patients with small hepatocellular carcinoma. Cancer 15: 1050-1055, 1996.
3. Kew MC: Hepatitis viruses and hepatocellular carcinoma. Res Virol 149: 257-262, 1998.
4. Kew MC: Interaction between hepatitis B and C viruses in hepatocellular carcinogenesis. J Viral Hepat 13: 145-149, 2006.
5. Lauren-Puig P, Legdix P, Bluteau O, Belghiti J, Franco D, Binot F, Monges G, Thomas G, Bioulac-Sage P and Zucman-Rossi J: Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 120: 1763-1773, 2001.
6. Lee SG and Rho HM: Transcriptional repression of the human p53 gene by hepatitis B viral X protein. Oncogene 19: 468-471, 2000.
7. Satyanarayana A, Manns MP and Rudolph KL: Telomeres and telomerase: a dual role in hepatocarcinogenesi. Hepatology 40: 276-283, 2004.
8. Tay N, Chan SH and Ren EC: Detection of integrated hepatitis B virus DNA in hepatocellular carcinoma cell lines by non radioactive in situ hybridization. J Med Virol 30(4): 266-271, 1990.
9. Hsu IC, Tokiwa T, Bennet W, Metcalf RA, Welsh SA, Sun T and Harris CC: P53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines. Carcinogenesis 14(5): 987-992, 1993.
10. Shiratori Y, Shiina S, Imamura M, Kato N, Kanai F, Okudaria T, Teratani T, Tohgo G, Toda N and Ohashi M: Characteristic difference of hepatocellular carcinoma between hepatitis B and C - viral infection in Japan. Hepatology 22: 1027-1033, 1995.
11. Poynard T, Yven MF, Ratziu V and Lai CL: Viral hepatitis C. Lancet 362: 1907-1917, 2003.
12. Fox SB, Taylor M, Grondahal-Hansen J, Kakolyris S and Gatter KC: Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer. J Pathol 195: 236-243, 2001.
13. Zheng Q, Tang ZY, Xue Q, Shi DR, Song HY and Tang HB: Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor. J Cancer Res Clin Oncol 126: 641-646, 2000.
14. Wing LR, Hawksworth GM, Bennet B and Booth NA: Clearance of t-PA, PAI-1 and t-PA-PAI-1 complex in an isolated perfused rat liver system. J Clin Med 117: 109-114, 1991.
15. Itoh T, Hayashi Y, Kanamaru T, Morita Y, Suzuki S, Wang W, Zhou L, Rui JA and Yamamoto M: Clinical significance of urokinase-type plasminogen activator activity in hepatocellular carcinoma. J Gastroenterol Hepatol 15: 422-430, 2000.
16. Zheng Q, Tang ZY, Xue Q, Shi DR, Song HY and Tang HB: Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor. J Cancer Res Clin Oncol 126: 641-646, 2000.
17. Fattovich G, Stroffolini T, Zagni I and Donato F: Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 127: S35-S50, 2004.
18. Anker P, Mulcahy H, Chen XQ and Stroun M: Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Rev 18: 65-73, 1999.
19. El-Houseini ME, Mohammed MS, Elshemey WM, Hussein T, Desouky OS and Elsayed A: Enhanced detection of hepatocellular carcinoma. Cancer Control 12(4): 248-253, 2005.
20. Gotoh M, Nakatani T, Masuda T, Mizuguchi Y, Sakamoto M, Tsuchiya R, Kato H and Furuta K: Prediction of invasive activities in hepatocellular carcinomas with special reference to alfa-fetoprotein and des-gamma-carboxiprothrombin. Jpn J Clin Oncol 33(10): 522-526, 2003.
21. Lee CM, Hsu CY, Eng HL, Huang WS, Lu SN and Changhien CS: Telomerase activity and telomerase catalytic subunit in hepatocellular carcinoma. Hepatogastroenterology 51: 796-800, 2004.
22. Onishi T, Nouso K, Higashi T, Toshikuni N, Nakatsukasa H and Kobayashi Y: Cellular distribution of telomerase reverse transcriptase in human hepatocellular carcinoma. J Gastroenterol Hepatol 18: 1168-1174, 2003.
23. Miura N, Horikawa I and Nishimoto A: Progressive telomere shortening and telomerase reactivation during hepatocellular carcinogenesis. Cancer Genet Cytogenet 93: 56-62, 1997.
24. Sozzi G, Conte D, Mariani L, Lo Vullo S, Roz L, Lombardo C, Pierotti MA and Tavecchio L: Analysis of circulating tumour DNA in plasma at diagnosis during follow-up of lung cancer patients. Cancer Res 61: 4675-4678, 2001.
25. Iizuka N, Sakaida I, Moribe T, Fujita N, Miura T, Stark M, Tamatsukuri S, Ishitsuka H, Uchida K, Terai S, Sakamoto K, Tamesa T and Oka M: Elevated levels of circulating cell-free DNA in the blood of patients with hepatitis C virus-associated hepatocellular carcinoma. Anticancer Res 26: 4713-4720, 2006.
26. Hu-Liang J, Qing-Hai Y, Lun-Xiu Q, Anuradha B, Marshonn F, Yidong C and Yin-Kun L: Gene expression profiling reveals potential biomarkers of human hepatocellular carcinoma. Clin Cancer Res 13(4): 1133-1139, 2007.
27. Tommasi S, Pinto R, Pilato B and Paradiso A: Molecular pathways and related target therapies in liver carcinoma. Current Pharm Des 13: 3279-3287, 2007.
28. Ren N, Qin LX, Tu H, Liu YK, Zhamg BH and Tang ZY: The prognostic value of circulating plasma DNA level and its allelic imbalance on chromosome 8p in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol 132: 399-407, 2006.
29. Wu TL, Zhang D, Chia JH, Tsao KH, Sun CF and Wu JT: Cell-free DNA: measurament in various carcinomas and establishment of normal reference range. Clin Chim Acta 321: 77-89, 2002.
30. Iizuka N, Oka M, Yamada-Okabe H, Mori N, Tamesa T, Okada T, Takemoto N, Tangoku A, Hamada K, Nakayama H, Miyamoto T, Uchimora S and Hamamoto Y: Comparison of gene expression profiles between hepatitis B virus- and hepatitis C virus-infected hepatocellular carcinoma by oligonucleotide microarray data based on a supervised learning method. Cancer Res 62: 3939-3944, 2002.
31. Iizuka N, Oka M, Yamada-Okabe H, Mori N, Tamesa T, Okada T, Takemoto N, Sakamoto K, Hamada K, Hamada K, Ishitsuka H, Miyamoto T, Uchimora S and Hamamoto Y: Self organizing map based molecular signature representing the devolopment of hepatocellular arcinoma. FEBS Lett 579: 1089-1100, 2005.
32. Dou J, Liu P, Wang J and Zhang X: Preliminary analysis of gene expression profiles in HepG2 cell line induced by different genotype core proteins of HCV cell. Mol Immunol 3: 227-233, 2006.
33. Stahl S, Ittrich C, Marx-Stoelting P, Kohle C, Altug-Teber O, Riess O, Bonin M, Jobst S, Kaiser S, Buchmann A and Schwarz M: Genotype-phenotype relationships in hepatocellular tumors from mice and man. Hepatology 42(2): 353-361, 2005.
34. Hsu HC, Yeng YM, Mao TL, Chu JS, Lai PL and Peng SY: Beta catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. Am J Pathol 157: 763-770, 2000.
35. Huang H, Fujii H, Sankila A, Mahler-Araujo BM, Matsuda M, Cathomas G and Ohgaki H: Beta-catenin mutations are frequent in human hepatocellular carcinomas associated with hepatitis C virus infection. Am J Pathol 155: 1795-1801, 1999.